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ABSTRACT
hepatocellular carcinoma (hCC) is the most common primary cancer of the liver and the third greatest 
cause of cancer-related death worldwide, incidence is increasing. The aim of this retrospective study is to es-
timate the incidence of hCC and to identify the risk factors for hCC in patients who have passed through the 
Clinic of hepatogastroenterology, Varna. All they have serologic tests, imaging examinations (abdominal 
ultrasonography, CT, MrI) and fine needle biopsy. Men are 125 of pts. and women are 55 (2.3:1). The average 
age at diagnosis is 62±9.44 (m) and 65±12,02 (f) years. The majority of patients (68%) with hCC had cirrho-
sis. Viral infection was found in 54% of the cases: hepatitis C (hCV) – 46 pts. (26%), hepatitis B (hBV) - 52 
pts (29%). Diabetes mellitus have 40 pts (22%). Alcohol abuse was observed in 38 pts. of the surveyed (21%). 
These study shows that the main risk factors for hCC are male gender, older age, viral hepatitis (hCV and 
hBV), alcohol intake, presence of cirrhosis and diabetes. Thus, the best strategy is eliminating modifiable 
risk factors (alcohol, diabetes) and to treat with viral infections (hBV, hCV). 
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INTRoDUCTIoN 
Hepatocellular carcinoma (HCC) is the most 
common primary cancer of the liver (1). Incidence is 
increasing and HCC has risen to become the 5th com-
monest malignancy worldwide and the third leading 
cause of cancer related death, exceeded only by can-
cers of the lung and stomach. The most recent World 
Health report, indicated a total of 714 600 new cases 
of HCC worldwide (Table 1), with 71% among men 
(Fig. 1) (6).
MATERIAL AND METHoDS
The aim of this retrospective study is to esti-
mate the incidence of HCC in patients with chronic 
liver diseases and to identify the risk factors for HCC 
in our group of in-patients. 17 450 adult in-patients 
have passed through the Clinic of Hepatogastroen-
terology, Varna, for the twelve-year period (Jan 2001- 
Dec 2012). HCC was established in 180 of them (1%). 
We interviewed all subjects regarding their alcohol 
consumption and background environment. All they 
have serologic tests, imaging examinations and fine 
needle biopsy. 
RESULTS
Men are 125 of pts. versus 55 women (2.3:1). The 
average age at diagnosis is 62±9.44 (m) and 65±12,02 
(f) years. The majority of patients (63%) with HCC 
had cirrhosis. Viral infection was found in 54% of 
the cases: hepatitis B (HBV) - 52 pts. (29%), hepati-
tis C (HCV) – 46 pts. (26%). Alcohol abuse was ob-
served in 38 pts. of the surveyed (21%). Working with 
harmful substances was found in three patients, and 
two patients had Wilsoǹ s disease. The most frequent 
combinations of risk factors are: cirrhosis with viral 
etiology - 55%; cirrhosis with ethanol - 68%. From 
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our data we can conclude that the main risk factors 











This pathology is associated with several risk 
factors, not only environmental but also genetic, 
generating an increasing interest in attaining a better 
understanding of this disease, which is still associ-
ated with very late diagnosis and poor prognosis (4). 
Major risk factors for HCC are viral (chron-
ic hepatitis B and chronic hepatitis C), toxic (alco-
hol and aflatoxins), metabolic (diabetes and non-al-
coholic fatty liver disease, Wilsoǹ s disease, heredi-
tary haemochromatosis) and immune-related dis-
eases. Most of these risk factors also lead to the for-
mation and progression of cirrhosis, which is present 
in 80 to 90% of patients with HCC and it is a risk fac-
tor also itself - 68% in our study. Over 80% of prima-
ry liver cancer worldwide is attributable to the effects 
of chronic infection with hepatitis B or C virus (HBV 
or HCV) - 46% in our study. Hepatitis B is consid-
ered the strongest risk factor associated with HCC in 
the majority of countries, but more important in Asia 
and Africa. The annual incidence of HCC in hepa-
Fig. 1. Worldwide incidence of Hepatocellular Cancer. Source: international Agency for research on Cancer 2013
Year (reference) Total number Male Females
1990 437 408 316 300 121 100
2000 564 300 398 364 165 972
2002 (The World health report, 2003) 714 600 504 600 210 000
Table 1. global frequency of new cases of hepatocellular carcinoma
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titis B patients with cirrhosis exceeds 2% (8). Hepa-
titis B virus is thought to be carcinogenic both di-
rectly and indirectly, because HBV DNA is integrat-
ed into cellular DNA of host and can be demonstrat-
ed in HCC cells in 95% of the cases (7). Hepatitis B 
infection is powerful oncogenic factor and may cause 
HCC without presence of cirrhosis - 5% in our study. 
That̀ s why antiviral therapy can prevent HCC. Early 
treatment intervention is necessary to prevent dam-
aging liver cells and decrease viral genome integra-
tion. Another important issue is that use of vaccines 
against HBV should eventually be of benefit, espe-
cially in endemic area (2).
Liver cancer has a higher prevalence in patients 
with HCV-associated cirrhosis than in non-viral eti-
ologies of chronic liver disease, while only a few cas-
es of HCV-associated HCC have been reported in the 
non-cirrhotic liver (1pts.), indicating that the virus 
possibly has a mutagenic effect. 
Cirrhosis is the major risk factor for the devel-
opment of HCC regardless of the cause. The annual 
incidence of HCC in patients of cirrhosis is about 3% 
(8). In our study we observed 123 patients with both 
cirrhosis and HCC – 68%.
In several studies conducted in Western coun-
tries, 30 to 40% of patients with hepatocellular car-
cinoma did not have chronic infection with HBV or 
HCV, suggesting the presence of other causes of dis-
ease - 44% in our study. Multiple non-viral factors 
have been implicated in the development of HCC. 
Increased body mass index and diabetes with sub-
sequent development of non-alcoholic steatohepati-
tis represent significant risk factors for HCC. More-
over diabetes mellitus is identified as a negative prog-
nostic indicator in hepatocellular carcinoma, though 
the basis for this is unknown (3,5). Other non-vi-
ral causes of HCC include iron overload syndromes, 
Wilson disease, α-1 antitrypsin deficiency, porphyr-
ias, autoimmune hepatitis, alcohol abuse, tobacco, 
oral contraceptive, aflatoxin, pesticides exposure. 
Our study shows 21% alcohol abuse in patients with 
HCC. 
CoNCLUSIoN
Those results show that the most important 
risk factors for HCC are male gender, older age, vi-
ral hepatitis (HCV and HBV), alcohol intake, pres-
ence of cirrhosis and diabetes. Thus, the best strategy 
is eliminating modifiable risk factors (alcohol, diabe-
tes) and to treat HBV and HCV infections with anti-
viral therapy. 
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